Cardialen, Inc. is a private company based in Minneapolis, MN. It was established in 2008 to develop an implantable defibrillator using low-electrical energy to restore normal heart rhythm and potentially avoid the negative side-effects of high-energy cardioversion shocks. The therapy is based on work by bioengineer Igor Efimov, whose federally-funded laboratory at George Washington University developed a way to defibrillate the heart without high-voltage shocks. Known as “unpinning termination” (UPT), the technique involves using a precisely timed series of low-voltage pulses to terminate an arrhythmia.
On October 2018 Cardialen announced that it had raised $17 million in a Series B funding round toward its goal. Cardialen stated that this funding would be used to continue clinical testing of the UPT concept in humans, and to start development of an implantable device to deliver the therapy.